Abstracts

Citation

James M. Oleske, M.D. PCP Prophylaxis (PRO) Among Children Followed in ACTG Pediatric Long-Term Protocol 219.

Citation

Pediatric HIV envelope vaccination: impact of maternal antibodies and relationship to childhood vaccine responses.

Citation

Pediatric Population Pharmacokinetics of Efavirenz (EFV) – High Dose Requirements in Infants Likely Due to Reduced Absorption. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

Citation

Lynne M. Mofenson, M.D., F.A.A.P., D. Robert Harris, Ph.D., E. Richard Stiehm, M.D., John S. Lambert, M.D., John ( Jack ) Moye, Jr., M.D., William A. Meyer, III, Ph.D. Performance Characteristics Of HIV-1 Culture, DNA PCR Or Quantitative RNA For Early Diagnosis OF Perinatal HIV-1 Infection.

Citation

Faith Doyle, R.N.,B.S.N. Perinatal AIDS Clinical trials - Integrating Research Into Primary Care "The Miami Experience".

Citation

Jim Aizire, Lillian Qambuzi Ogwang, Alla Sikorskii, Macpherson Mallewa , Itziar Familiar, Alex Mutebe, Newton Kumwenda, Taha Taha, Michael Boivin, Mary Glenn Fowler. Perinatal HIV and ARV exposure is associated with poor growth among Ugandan Children. Presented at: CROI 2016.

Citation

David E. Shapiro, Ph.D., Petronella Muresan, M.S., Lynne M. Mofenson, M.D., F.A.A.P., Mary Glenn Fowler, M.D., M.P.H., George D. McSherry, M.D., Russell B. Van Dyke, M.D. Perinatal zidovudine (AZT) exposure in PACTG 076 and long term effect on hematologic parameters in HIV-exposed but uninfected children. Presented at: XV International Conference on AIDS.

Citation

Sharon Appelbaum Nachman, M.D., Edward P. Acosta, Pharm.D., Pearl Samson, M.S., Hedy Teppler, M.D., Carolee Welebob, Terence Fenton, Ed.D., Edward Handelsman, M.D., Carol J. Worrell, M.D., Bobbie L. Graham, B.S., Andrew A. Wiznia, M.D. Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth. Presented at: 17th Conference on Retroviruses & Opportunistic Infections.

Citation

Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth. Presented at: 17th Conference on Retroviruses & Opportunistic Infections.

Citation

T Ruel, E Acosta, R Singh, C Alvero, T Fenton, K George, S Popson, E Townley, R Hazra, C Brothers, C Vavro, A Buchanan, A Wiznia, IMPAACT P1093 team. Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to 6 years: Results from IMPAACT P1093. Presented at: IAS 2018.